| Summary: | We report a case of a 70-year-old woman undergoing chemotherapy with capecitabine for breast cancer who presented with a diffuse erythematous facial eruption, consistent with actinic keratosis activation. The emergence of subclinical actinic keratosis with capecitabine treatment is most likely due to this medication being a prodrug of 5-fluorouracil, a commonly used topical treatment for actinic keratosis. Since this adverse reaction is usually self-resolving and can be easily treated, chemotherapy cessation is usually not recommended. Awareness and prompt recognition of this potential adverse effect of capecitabine can prevent discontinuation or delay of chemotherapy.
|
|---|
